1. Home
  2. IPHA vs INVZ Comparison

IPHA vs INVZ Comparison

Compare IPHA & INVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPHA
  • INVZ
  • Stock Information
  • Founded
  • IPHA 1999
  • INVZ 2016
  • Country
  • IPHA France
  • INVZ Israel
  • Employees
  • IPHA N/A
  • INVZ N/A
  • Industry
  • IPHA Biotechnology: Pharmaceutical Preparations
  • INVZ Auto Parts:O.E.M.
  • Sector
  • IPHA Health Care
  • INVZ Consumer Discretionary
  • Exchange
  • IPHA Nasdaq
  • INVZ Nasdaq
  • Market Cap
  • IPHA 160.1M
  • INVZ 144.1M
  • IPO Year
  • IPHA 2019
  • INVZ N/A
  • Fundamental
  • Price
  • IPHA $2.34
  • INVZ $0.76
  • Analyst Decision
  • IPHA Strong Buy
  • INVZ Strong Buy
  • Analyst Count
  • IPHA 1
  • INVZ 5
  • Target Price
  • IPHA $11.00
  • INVZ $3.24
  • AVG Volume (30 Days)
  • IPHA 31.8K
  • INVZ 1.6M
  • Earning Date
  • IPHA 03-27-2025
  • INVZ 05-14-2025
  • Dividend Yield
  • IPHA N/A
  • INVZ N/A
  • EPS Growth
  • IPHA N/A
  • INVZ N/A
  • EPS
  • IPHA N/A
  • INVZ N/A
  • Revenue
  • IPHA $20,831,349.00
  • INVZ $24,268,000.00
  • Revenue This Year
  • IPHA $209.83
  • INVZ $130.12
  • Revenue Next Year
  • IPHA $83.96
  • INVZ $135.62
  • P/E Ratio
  • IPHA N/A
  • INVZ N/A
  • Revenue Growth
  • IPHA N/A
  • INVZ 16.25
  • 52 Week Low
  • IPHA $1.29
  • INVZ $0.45
  • 52 Week High
  • IPHA $3.51
  • INVZ $3.14
  • Technical
  • Relative Strength Index (RSI)
  • IPHA 71.42
  • INVZ 53.93
  • Support Level
  • IPHA $2.13
  • INVZ $0.70
  • Resistance Level
  • IPHA $2.34
  • INVZ $0.78
  • Average True Range (ATR)
  • IPHA 0.14
  • INVZ 0.05
  • MACD
  • IPHA 0.04
  • INVZ 0.01
  • Stochastic Oscillator
  • IPHA 90.07
  • INVZ 56.70

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

About INVZ Innoviz Technologies Ltd. Ordinary shares

Innoviz Technologies Ltd is a provider of solid-state LiDAR and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles, buses and trucks and other industries that require 3-dimensional high resolution sensors. Company's solutions can enable safe autonomy for industries like logistics, drones, robotics, construction and other industrial applications, agriculture, smart city, smart infrastructure, security and mapping.

Share on Social Networks: